Substituted pyrroline kinase inhibitors

Abstract

The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

1 . A pharmaceutical composition comprising a compound of Formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R is selected from the group consisting of R a , —C 1-8 alkyl-R a , —C 2-8 alkenyl-R a , —C 2-8 alkynyl-R a  and cyano; 
         R a  is selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl; 
         R 1  is selected from the group consisting of hydrogen, —C 1-8 alkyl-R 5 , —C 2-8 alkenyl-R 5 —C 2-8 alkynyl-R 5 , —C(O)—(C 1-8 )alkyl-R 9 , —C(O)-aryl-R 8 , —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—NH(aryl-R 8 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , -cycloalkyl-R 6 , -heterocyclyl-R 6 , -aryl-R 6  and -heteroaryl-R 6 ; wherein heterocyclyl and heteroaryl are attached to the azaindole nitrogen atom in the one position via a heterocyclyl or heteroaryl ring carbon atom; 
         R 5  is 1 to 2 substituents independently selected from the group consisting of hydrogen, —O—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-OH, —O—(C 1-8 )alkyl-O—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-NH 2 , —O—(C 1-8 )alkyl-NH(C 1-8 alkyl), —O—(C 1-8 )alkyl-N(C 18 alkyl) 2 , —O—(C 1-8 )alkyl-S—(C 1-8 )alkyl , —O—(C 1-8 )alkyl-SO 2 —(C 1-8 )alkyl, —O—(C 1-8 )alkyl-SO 2 —NH 2 , —O—(C 1-8 )alkyl-SO 2 —NH(C 1-8 alkyl), —O—(C 1-8 )alkyl-SO 2 —N(C 1-8 alkyl) 2 , —O—C(O)H, —O—C(O)—(C 1-8 )alkyl, —O—C(O)—NH 2 , —O—C(O)—NH(C 1-8 alkyl), —O—C(O)—N(C 1-8 alkyl) 2 , —O—(C 1-8 )alkyl-C(O)H, —O—(C 1-8 )alkyl-C(O)—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-CO 2 H, —O—(C 1-8 )alkyl-C(O)—O—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-C(O)—NH 2 , —O—(C 1-8 )alkyl-C(O)—NH(C 1-8 alkyl), —O—(C 1-8 )alkyl-C(O)—N(C 1-8 alkyl) 2 , —C(O)H, —C(O)—(C 1-8 )alkyl, —CO 2 H, —C(O)—O—(C 1-8 )alkyl, —C(O)—NH 2 , —C(NH)—NH 2 , —C(O)—NH(C 1-8 alkyl), —C(O)—N(C 1-8 alkyl) 2 , —SH, —S—(C 1-8 )alkyl, —S—(C 1-8 )alkyl-S—(C 1-8 )alkyl, —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl, —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-OH, —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-NH 2 , —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-NH(C 1-8 alkyl), —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-N(C 1-8 alkyl) 2 , —S—(C 1-8 )alkyl-NH(C 1-8 alkyl), —SO 2 —(C 1-8 )alkyl, —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl), —SO 2 —N(C 1-8 alkyl) 2 , —N—R 7 , cyano, (halo) 1-3 , hydroxy, nitro, oxo, -cycloalkyl-R 6 , -heterocyclyl-R 6 , -aryl-R 6  and -heteroaryl-R 6 ; 
         R 6  is 1 to 4 substituents attached to a carbon or nitrogen atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C(O)H, —C(O)—(C 1-8 )alkyl, —CO 2 H, —C(O)—O—(C 1-8 )alkyl, —C(O)—NH 2 , —C(NH)—NH 2 , —C(O)—NH(C 1-8 alkyl), —C(O)—N(C 1-8 )alkyl) 2 , —SO 2 —(C 1-8 )alkyl, —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl), —SO 2 —N(C 1-8 alkyl) 2 , —(C 1-8 )alkyl-N—R 7 , —(C 1-8 )alkyl-(halo) 1-3 , —(C 1-8 )alkyl-OH, -aryl-R 8 , —(C 1-8 )alkyl-aryl-R 8  and —(C 1-8 )alkyl-heteroaryl-R 8 ; with the proviso that, when R 6  is attached to a carbon atom, R 6  is further selected from the group consisting of —C 1-8 alkoxy, —(C 1-8 )alkoxy-(halo) 1-3 , —SH, —S—(C 1-8 )alkyl, —N—R 7 , cyano, halo, hydroxy, nitro, oxo and -heteroaryl-R 8 ; 
         R 7  is 2 substituents independently selected from the group consisting of hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —(C 1-8 )alkyl-OH, —(C 1-8 )alkyl-O—(C 1-8 )alkyl, —(C 1-8 )alkyl-NH 2 , —(C 1-8 )alkyl-NH(C 1-8 alkyl), —(C 1-8 )alkyl-N(C 1-8 alkyl) 2 , —(C 1-8 )alkyl-S—(C 1-8 )alkyl, —C(O)H, —C(O)—(C 1-8 )alkyl, —C(O)—O—(C 1-8 )alkyl, —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl), —C(O)—N(C 1-8 alkyl) 2 , —SO 2 —(C 1-8 )alkyl, —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl), —SO 2 —N(C 1-8 alkyl) 2 , —C(N)—NH 2 , -cycloalkyl-R 8 , —(C 1-8 )alkyl-heterocyclyl-R 8 , -aryl-R 8 , —(C,  8 )alkyl-aryl-R 8  and —(C 1-8 )alkyl-heteroaryl-R 8 ; 
         R 8  is 1 to 4 substituents attached to a carbon or nitrogen atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl, —(C 1-8 )alkyl-(halo) 1-3  and —(C 1-8 )alkyl-OH; 
         with the proviso that, when R 8  is attached to a carbon atom, R 8  is further selected from the group consisting of —C 1-8 alkoxy, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 , cyano, halo, —(C 1-8 )alkoxy-(halo) 1-3 , hydroxy and nitro; 
         R 9  is 1 to 2 substituents independently selected from the group consisting of hydrogen, —C 1-8 alkoxy, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 , cyano, (halo) 1-3 , hydroxy and nitro; 
         R 2  is one substituent attached to a carbon or nitrogen atom selected from the group consisting of hydrogen, —C 1-8 alkyl-R 5 , —C 2-8 alkenyl-R 5 , —C 2-8 alkynyl-R 5 , —C(O)H, —C(O)—(C 1-8 )alkyl-R 9 , —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —C(O)—NH(aryl-R 8 ), —C(O)-cycloalkyl-R 8  , —C(O)-heterocyclyl-R 8  , —C(O)-aryl-R 8 , —C(O)-heteroaryl-R 8 , —CO 2 H, —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , -cycloalkyl-R 6 , -aryl-R 6  and —(C 1-8 )alkyl-N—R 7 ; 
         with the proviso that, when R 2  is attached to a carbon atom, R 2  is further selected from the group consisting of —C 1-8 alkoxy-R 5 , —N—R 7 , cyano, halogen, hydroxy, nitro, oxo, -heterocyclyl-R 6  and -heteroaryl-R 6 ; 
         R 3  is 1 to 3 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl-R 10 , —C 2-8 alkenyl-R 10 , —C 2-8 alkynyl-R 10 , —C 1-8 alkoxy-R 10 , —C(O)H, —C(O)—(C 1-8 )alkyl-R 9 , —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —C(O)-cycloalkyl-R 8 , —C(O)-heterocyclyl-R 8 , —C(O)-aryl-R 8 , —C(O)-heteroaryl-R 8 , —C(NH)—NH 2 , —CO 2 H, —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , —N—R 7 , cyano, halogen, hydroxy, nitro, -cycloalkyl-R 8 , -heterocyclyl-R 8 , -aryl-R 8  and -heteroaryl-R 8 ; 
         R 4  is 1 to 4 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl-R 10 , —C 2-8 alkenyl-R 10 , —C 2-8 alkynyl-R 10 , —C 1-8 alkoxy-R 10 , —C(O)H, —C(O)—(C 1-8 )alkyl-R 9 , —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —C(O)-cycloalkyl-R 8 , —C(O)-heterocyclyl-R 8 , —C(O)-aryl-R 8 , —C(O)-heteroaryl-R 8 , —C(NH)—NH 2 , —CO 2 H, —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —SH, —S—(C 1-8 )alkyl-R 10 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl-R 9 ), —SO 2 —N(C 1-8 alkyl-R 9 ) 2 , —N—R 7 , cyano, halogen, hydroxy, nitro, -cycloalkyl-R 8 , -heterocyclyl-R 8 , -aryl-R 8  and -heteroaryl-R 8 ; 
         R 10  is 1 to 2 substituents independently selected from the group consisting of hydrogen, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 , cyano, (halo) 1-3 , hydroxy, nitro and oxo; and, 
         Y and Z are independently selected from the group consisting of O, S, (H,OH) and (H,H); with the proviso that one of Y and Z is O and the other is selected from the group consisting of O, S, (H,OH) and (H,H); and pharmaceutically acceptable salts thereof; and 
         a pharmaceutically acceptable carrier. 
       
     
     
         2 . A method for preparing a pharmaceutical composition comprising mixing a compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         3 . A method for treating or ameliorating a kinase mediated disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R is selected from the group consisting of R a , —C 1-8 alkyl-R a , —C 2-8 alkenyl-R a , —C 2-8 alkynyl-R a  and cyano; 
         R a  is selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl; 
         R 1  is selected from the group consisting of hydrogen, —C 1-8 alkyl-R 5  —C 2-8 alkenyl-R 5 , —C 2-8 alkynyl-R 5 , —C(O)—(C 1-8 )alkyl-R 9 , —C(O)-aryl-R 8 , —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—NH(aryl-R 8 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , -cycloalkyl-R 6 , -heterocyclyl-R 6 , -aryl-R 6  and -heteroaryl-R 6 ; wherein heterocyclyl and heteroaryl are attached to the azaindole nitrogen atom in the one position via a heterocyclyl or heteroaryl ring carbon atom; 
         R 5  is 1 to 2 substituents independently selected from the group consisting of hydrogen, —O—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-OH, —O—(C 1-8 )alkyl-O—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-NH 2 , —O—(C 1-8 )alkyl-NH(C 1-8 alkyl), —O—(C 1-8 )alkyl-N(C 1-8 alkyl) 2 , —O—(C 1-8 )alkyl-S—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-SO 2 —(C 1-8 )alkyl, —O—(C 1-8 )alkyl-SO 2 —NH 2 , —O—(C 1-8 )alkyl-SO 2 —NH(C 1-8 alkyl), —O—(C 1-8 )alkyl-SO 2 —N(C 1-8 alkyl) 2 , —O—C(O)H, —O—C(O)—(C 1-8 )alkyl, —O—C(O)—NH 2 , —O—C(O)—NH(C 1-8 alkyl), —O—C(O)—N(C 1-8 alkyl) 2 , —O—(C 1-8 )alkyl-C(O)H, —O—(C 1-8 )alkyl-C(O)—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-CO 2 H, —O—(C 1-8 )alkyl-C(O)—O—(C 1-8 )alkyl, —O—(C 1-8 )alkyl-C(O)—NH 2 , —O—(C 1-8 )alkyl-C(O)—NH(C 1-8 alkyl), —O—(C 1-8 )alkyl-C(O)—N(C 1-8 alkyl) 2 , —C(O)H, —C(O)—(C 1-8 )alkyl, —CO 2 H, —C(O)—O—(C 1-8 )alkyl, —C(O)—NH 2 , —C(NH)—NH 2 , —C(O)—NH(C 1-8 alkyl), —C(O)—N(C 1-8 alkyl) 2 , —SH, —S—(C 1-8 )alkyl, —S—(C 1-8 )alkyl-S—(C 1-8 )alkyl, —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl, —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-OH, —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-NH 2 , —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-NH(C 1-8 alkyl), —S—(C 1-8 )alkyl-O—(C 1-8 )alkyl-N(C 1-8 alkyl) 2 , —S—(C 1-8 )alkyl-NH(C 1-8 alkyl), —SO 2 —(C 1-8 )alkyl, —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl), —SO 2 —N(C 1-8 alkyl) 2 , —N—R 7 , cyano, (halo) 1-3 , hydroxy, nitro, oxo, -cycloalkyl-R 6 , -heterocyclyl-R 6 , -aryl-R 6  and -heteroaryl-R 6 ; 
         R 6  is 1 to 4 substituents attached to a carbon or nitrogen atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C(O)H, —C(O)—(C 1-8 )alkyl, —CO 2 H, —C(O)—O—(C 1-8 )alkyl, —C(O)—NH 2 , —C(NH)—NH 2 , —C(O)—NH(C 1-8 alkyl), —C(O)—N(C 1-8 )alkyl) 2 , —SO 2 —(C 1-8 )alkyl, —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl), —SO 2 —N(C 1-8 alkyl) 2 , —(C 1-8 )alkyl-N—R 7 , —(C 1-8 )alkyl-(halo) 1-3 , —(C 1-8 )alkyl-OH, -aryl-R 8 , —(C 1-8 )alkyl-aryl-R 8  and —(C 1-8 )alkyl-heteroaryl-R 8 ; 
         with the proviso that, when R 6  is attached to a carbon atom, R 6  is further selected from the group consisting of —C 1-8 alkoxy, —(C 1-8 )alkoxy-(halo) 1-3 , —SH, —S—(C 1-8 )alkyl, —N—R 7 , cyano, halo, hydroxy, nitro, oxo and -heteroaryl-R 8 ; 
         R 7  is 2 substituents independently selected from the group consisting of hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —(C 1-8 )alkyl-OH, —(C 1-8 )alkyl-O—(C 1-8 )alkyl, —(C 1-8 )alkyl-NH 2 , —(C 1-8 )alkyl-NH(C 1-8 alkyl), —(C 1-8 )alkyl-N(C 1-8 alkyl) 2 , —(C 1-8 )alkyl-S—(C 1-8 )alkyl, —C(O)H, —C(O)—(C 1-8 )alkyl, —C(O)—O—(C 1-8 )alkyl, —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl), —C(O)—N(C 1-8 alkyl) 2 , —SO 2 —(C 1-8 )alkyl, —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl), —SO 2 —N(C 1-8 alkyl) 2 , —C(N)—NH 2 , -cycloalkyl-R 8 , —(C 1-8 )alkyl-heterocyclyl-R 8 , -aryl-R 8 , —(C 1-8 )alkyl-aryl-R 8  and —(C 1-8 )alkyl-heteroaryl-R 8 ; 
         R 8  is 1 to 4 substituents attached to a carbon or nitrogen atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl, —(C 1-8 )alkyl-(halo) 1-3  and —(C 1-8 )alkyl-OH; 
         with the proviso that, when R 8  is attached to a carbon atom, R 8  is further selected from the group consisting of —C 1-8 alkoxy, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 , cyano, halo, —(C 1-8 )alkoxy-(halo) 1-3 , hydroxy and nitro; 
         R 9  is 1 to 2 substituents independently selected from the group consisting of hydrogen, —C 1-8 alkoxy, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 , cyano, (halo) 1-3 , hydroxy and nitro; 
         R 2  is one substituent attached to a carbon or nitrogen atom selected from the group consisting of hydrogen, —C 1-8 alkyl-R 5 , —C 2-8 alkenyl-R 5 , —C 2-8 alkynyl-R 5 , —C(O)H, —C(O)—(C 1-8 )alkyl-R 9 , —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —C(O)—NH(aryl-R 8 ), —C(O)-cycloalkyl-R 8 , —C(O)-heterocyclyl-R 8 , —C(O)-aryl-R 8 , —C(O)-heteroaryl-R 8 , —CO 2 H, —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , -cycloalkyl-R 6 , -aryl-R 6  and —(C 1-8 )alkyl-N—R 7 ; 
         with the proviso that, when R 2  is attached to a carbon atom, R 2  is further selected from the group consisting of —C 1-8 alkoxy-R 5 , —N—R 7 , cyano, halogen, hydroxy, nitro, oxo, -heterocyclyl-R 6  and -heteroaryl-R 6 ; 
         R 3  is 1 to 3 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl-R 10 , —C 2-8 alkenyl-R 10 , —C 2-8 alkynyl-R 10 , —C 1-8 alkoxy-R 10 , —C(O)H, —C(O)—(C 1-8 )alkyl-R 9 , —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —C(O)-cycloalkyl-R 8 , —C(O)-heterocyclyl-R 8 , —C(O)-aryl-R 8 , —C(O)-heteroaryl-R 8 , —C(NH)—NH 2 , —CO 2 H, —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , —N—R 7 , cyano, halogen, hydroxy, nitro, -cycloalkyl-R 8 , -heterocyclyl-R 8 , -aryl-R 8  and -heteroaryl-R 8 ; 
         R 4  is 1 to 4 substituents attached to a carbon atom independently selected from the group consisting of hydrogen, —C 1-8 alkyl-R 10 , —C 2-8 alkenyl-R 10 , —C 2-8 alkynyl-R 10 , —C 1-8 alkoxy-R 10 , —C(O)H, —C(O)—(C 1-8 )alkyl-R 9 , —C(O)—NH 2 , —C(O)—NH(C 1-8 alkyl-R 9 ), —C(O)—N(C 1-8 alkyl-R 9 ) 2 , —C(O)-cycloalkyl-R 8 , —C(O)-heterocyclyl-R 8 , —C(O)-aryl-R 8 , —C(O)-heteroaryl-R 8 , —C(NH)—NH 2 , —CO 2 H, —C(O)—O—(C 1-8 )alkyl-R 9 , —C(O)—O-aryl-R 8 , —SH, —S—(C 1-8 )alkyl-R 10 , —SO 2 —(C 1-8 )alkyl-R 9 , —SO 2 -aryl-R 8 , —SO 2 —NH 2 , —SO 2 —NH(C 1-8 alkyl-R 9 ), —SO 2 —N(C 1-8 alkyl-R 9 ) 2 , —N—R 7 , cyano, halogen, hydroxy, nitro, -cycloalkyl-R 8 , -heterocyclyl-R 8 , -aryl-R 8  and -heteroaryl-R 8 ; 
         R 10  is 1 to 2 substituents independently selected from the group consisting of hydrogen, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 , cyano, (halo) 1-3 , hydroxy, nitro and oxo; and, 
         Y and Z are independently selected from the group consisting of O, S, (H,OH) and (H,H); with the proviso that one of Y and Z is O and the other is selected from the group consisting of O, S, (H,OH) and (H,H); and pharmaceutically acceptable salts thereof. 
       
     
     
         4 . The method of  claim 3  wherein the disorder is mediated by selective inhibition of a kinase selected from the group consisting of glycogen synthase kinase-3 and protein kinase C. 
     
     
         5 . The method of  claim 4  wherein the kinase is selected from the group consisting of glycogen synthase kinase-3β and protein kinase C α, protein kinase C β-II, protein kinase C γ. 
     
     
         6 . The method of  claim 3  wherein the disorder is mediated by dual inhibition of at least two kinases selected from the group consisting of glycogen synthase kinase-3 and protein kinase C. 
     
     
         7 . The method of  claim 6  wherein at least two kinases are selected from the group consisting of glycogen synthase kinase-3β and protein kinase C α, protein kinase C β-II, protein kinase C γ. 
     
     
         8 . The method of  claim 3  wherein the therapeutically effective amount of the compound of  claim 1  is from about 0.001 mg/kg/day to about 300 mg/kg/day. 
     
     
         9 . The method of  claim 3  wherein the kinase mediated disorder is selected from the group consisting of cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and CNS disorders. 
     
     
         10 . The method of  claim 9  wherein cardiovascular diseases are selected from the group consisting of acute stroke, heart failure, cardiovascular ischemia, thrombosis, atherosclerosis, hypertension, restenosis, retinopathy of prematurity and age-related macular degeneration. 
     
     
         11 . The method of  claim 9  wherein diabetes is selected from the group consisting of insulin dependent diabetes and Type II non-insulin dependent diabetes mellitus. 
     
     
         12 . The method of  claim 9  wherein diabetes-associated disorders are selected from the group consisting of impaired glucose tolerance, diabetic retinopathy, proliferative retinopathy, retinal vein occlusion, macular edema, cardiomyopathy, nephropathy and neuropathy. 
     
     
         13 . The method of  claim 9  wherein inflammatory diseases are selected from the group consisting of vascular permeability, inflammation, asthma, rheumatoid arthritis and osteoarthritis. 
     
     
         14 . The method of  claim 9  wherein immunological disorders are selected from the group consisting of transplant tissue rejection, HIV-1 and PKC modulated immunological disorders. 
     
     
         15 . The method of  claim 9  wherein dermatological disorders are selected from the group consisting of psoriasis, hair loss and baldness. 
     
     
         16 . The method of  claim 9  wherein oncological disorders are selected from the group consisting of cancer or tumor growth, proliferative angiopathy and angiogenesis. 
     
     
         17 . The method of  claim 9  wherein central nervous system disorders are selected from the group consisting of chronic pain, neuropathic pain, epilepsy, chronic neurodegenerative conditions, dementia, Alzheimer's disease, mood disorders, schizophrenia, manic depression and neurotraumatic, cognitive decline and ischemia-related diseases (as a result of head trauma or transient ischemic stroke). 
     
     
         18 . The method of  claim 3  further comprising a method for use for said compound as an adjunct to chemotherapy and radiation therapy. 
     
     
         19 . A method for treating or ameliorating a kinase mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of  claim 1 . 
     
     
         20 . The method of  claim 19  wherein the therapeutically effective amount of a pharmaceutical composition of  claim 20  is from about 0.001 mg/kg/day to about 300 mg/kg/day.